Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Change in Cash (2017 - 2025)

Crinetics Pharmaceuticals has reported Change in Cash over the past 9 years, most recently at -$9.8 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 81.49% year-over-year to -$9.8 million; the TTM value through Dec 2025 reached -$163.4 million, down 177.94%, while the annual FY2025 figure was -$163.4 million, 177.94% down from the prior year.
  • Change in Cash for Q4 2025 was -$9.8 million at Crinetics Pharmaceuticals, down from $57.2 million in the prior quarter.
  • Over five years, Change in Cash peaked at $341.0 million in Q1 2024 and troughed at -$170.0 million in Q1 2025.
  • A 5-year average of $442750.0 and a median of -$5.7 million in 2023 define the central range for Change in Cash.
  • On a YoY basis, Change in Cash climbed as much as 3902.19% in 2024 and fell as far as 5613.71% in 2024.
  • Year by year, Change in Cash stood at $39.2 million in 2021, then plummeted by 95.5% to $1.8 million in 2022, then plummeted by 5091.37% to -$87.9 million in 2023, then soared by 40.02% to -$52.7 million in 2024, then skyrocketed by 81.49% to -$9.8 million in 2025.
  • Business Quant data shows Change in Cash for CRNX at -$9.8 million in Q4 2025, $57.2 million in Q3 2025, and -$40.8 million in Q2 2025.